Atlas Trials

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Clinical trial NCT02630186 · TERMINATED

Trial details

NCT number
NCT02630186
Sponsor
Clovis Oncology, Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2016-02-24
Primary completion
2017-09-05
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.